Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.
One hundred eighty human immunodeficiency virus (HIV)- and hepatitis C virus (HCV)-coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 (30%) were eligible for treatment and 105 (70%) were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.
Fleming
Catherine A
CA
Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA. catherine.fleming@bmc.org
Craven
Donald E
DE
Thornton
David
D
Tumilty
Sheila
S
Nunes
David
D
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004608:Eligibility Determination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D014504:Urban Health; D014505:Urban Population
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons